Literature DB >> 35949878

Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis.

Eyad Ahmed1, Kok Hoe Chan1, Sindhusha Veeraballi1, Theodore Dacosta2, Hamid Shaaban3.   

Abstract

Entities:  

Year:  2021        PMID： 35949878      PMCID： PMC9326375          DOI： 10.46497/ArchRheumatol.2022.8898

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN： 2148-5046            Impact factor:   1.007


× No keyword cloud information.
  7 in total

Review 1.  Management of Evans syndrome.

Authors:  Alice Norton; Irene Roberts
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Fulminant Colitis Following Rituximab Therapy.

Authors:  Seth Lipka; Seymour Katz; James M Crawford
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01

Review 3.  Serologic markers in inflammatory bowel disease.

Authors:  Xavier Bossuyt
Journal:  Clin Chem       Date:  2005-12-08       Impact factor: 8.327

4.  Severe ulcerative colitis after rituximab therapy.

Authors:  Daniela S Ardelean; Tanja Gonska; Shannon Wires; Ernest Cutz; Anne Griffiths; Elizabeth Harvey; Shirley M L Tse; Susanne M Benseler
Journal:  Pediatrics       Date:  2010-06-21       Impact factor: 7.124

5.  Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.

Authors:  Keith Leiper; Kate Martin; Anthony Ellis; Sreedhar Subramanian; Alastair J Watson; Steve E Christmas; Deborah Howarth; Fiona Campbell; Jonathan M Rhodes
Journal:  Gut       Date:  2011-04-06       Impact factor: 23.059

6.  Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.

Authors:  Muhammad Kashif; Adnan Qureshi; Salman Naseem Adil; Mohammad Khurshid
Journal:  J Pak Med Assoc       Date:  2010-01       Impact factor: 0.781

Review 7.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.